Barclays
CTKB icon

Barclays’s Cytek Biosciences CTKB Stock Holding History

Barclays’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$106K Sell
24,143
-159,096
-87% -$751K ﹤0.01% 3999
2025
Q4 		$925K Buy
183,239
+17,667
+11% +$82K ﹤0.01% 3482
2025
Q3 		$575K Sell
165,572
-222,336
-57% -$835K ﹤0.01% 3722
2025
Q2 		$1.32M Buy
387,908
+235,045
+154% +$783K ﹤0.01% 3148
2025
Q1 		$613K Sell
152,863
-62,561
-29% -$324K ﹤0.01% 3395
2024
Q4 		$1.4M Buy
215,424
+14,065
+7% +$83.8K ﹤0.01% 3153
2024
Q3 		$1.12M Buy
201,359
+154,915
+334% +$878K ﹤0.01% 3288
2024
Q2 		$259K Sell
46,444
-60,174
-56% -$361K ﹤0.01% 3433
2024
Q1 		$715K Sell
106,618
-82,725
-44% -$654K ﹤0.01% 3356
2023
Q4 		$1.73M Buy
189,343
+140,164
+285% +$882K ﹤0.01% 3031
2023
Q3 		$271K Buy
49,179
+411
+0.8% +$3.3K ﹤0.01% 3136
2023
Q2 		$416K Sell
48,768
-9,021
-16% -$80.9K ﹤0.01% 2870
2023
Q1 		$531K Buy
57,789
+27,130
+88% +$292K ﹤0.01% 3229
2022
Q4 		$313K Buy
30,659
+25,818
+533% +$347K ﹤0.01% 3597
2022
Q3 		$71K Sell
4,841
-12,810
-73% -$166K ﹤0.01% 3667
2022
Q2 		$189K Sell
17,651
-15,005
-46% -$149K ﹤0.01% 3459
2022
Q1 		$351K Buy
+32,656
New +$441K ﹤0.01% 3114

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barclays's CTKB Position: Q1 2026 in Review

Barclays reduced its Cytek Biosciences (CTKB) stake by 87% in Q1 2026, selling an estimated $751K and leaving 24,143 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #3999.

Barclays first reported a position in CTKB in Q1 2022 and has held it in 17 quarters since. The position peaked at $1.73M in Q4 2023. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Barclays held 24,143 shares of Cytek Biosciences worth $106K as of Q1 2026.
  • Barclays sold 159,096 Cytek Biosciences shares in Q1 2026, an estimated $751K.
  • Cytek Biosciences made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3999 holding.
  • Barclays first reported a position in Cytek Biosciences in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Cytek Biosciences position peaked at $1.73M in Q4 2023.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.